Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen
(PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in
participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously
progressed on at least one prior androgen pathway inhibitor (e.g., abiraterone, enzalutamide,
apalutamide).
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Merck Sharp & Dohme LLC Prostate Cancer Foundation